EMPOWERing the Next Generation

News
Article

An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

CONFERENCE REPORTER

Erica Koenig, PhD, gives an overview of Cerevel Therapeutics and discusses EMPOWER, a phase 2 clinical trial evaluating emraclidine for the treatment of schizophrenia. Koenig presented this research in a poster presentation at Psych Congress 2023.

Dr Koenig is program lead of emraclidine and senior director of global clinical development at Cerevel Therapeutics.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2023 MJH Life Sciences

All rights reserved.